CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in port-au-prince Haiti

Journal of Infectious Diseases

Volumn 200, Issue 6, 2009, Pages 955-964

  Leger, Paul ^a   Dillingham, Rebecca ^b   Beauharnais, Carole Anne ^a   Kashuba, Angela D M ^c   Rezk, Naser L ^c   Fitzgerald, Daniel W ^a,d   Pape, Jean William ^a,d   Haas, David W ^e  

^a Department of Adolescent Medicine   (Haïti)

^b UNIVERSITY OF VIRGINIA   (United States)

^c University of North Carolina   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; N DEMETHYLASE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EVENING DOSAGE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; GENETICS; HAPLOTYPE; METABOLISM; NUCLEOTIDE SEQUENCE;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BENZOXAZINES; FEMALE; HAITI; HAPLOTYPES; HIV INFECTIONS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC;

EID: 70349432367     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605126     Document Type: Article

References (39)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessed 27 January 2009.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Available at: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 27 January 2009.
3. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873 (Pubitemid 29411350)
4. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-1861
5. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 2006;354:251-260
6. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106 (Pubitemid 351679596)
7. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
8. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400
9. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of longterm responses to antiretroviral regimens containing efavirenz and/ or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005;192:1931-1942
10. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5. (Pubitemid 43205520)
11. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-198 (Pubitemid 43312581)
12. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected individuals. Clin Pharmacol Ther 2007;81:557-566 (Pubitemid 46454205)
13. Haas DW, Ribaudo H, Motsinger A, et al. Pharmacogenetics of plasma drug exposure and treatment outcomes with efavirenz (EFV)-containing regimens: an AIDS Clinical Trials Group (ACTG) study [abstract L-139]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2008.
14. Single Nucleotide Polymorphism Database. National Center for Bioinformatics Web site. Available at: http://www.ncbi.nlm.nih.gov/SNP/index. html. Accessed 27 January 2009.
15. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40:507-519
16. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47:130-137 (Pubitemid 36070353)
17. Ribaudo H, Clifford D, Gulick R, et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologie response, and race: results from ACTG A5095/A5097s [abstract 132], In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
18. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available at: http://www.cypalleles.ki.se/. Accessed 27 January 2009.
19. Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/ NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008;36:169-181
20. SeattleSNPs Variation Discovery Resource Web site. Available at: http://pga.gs.washington.edu/. Accessed 27 January 2009.
21. Haas DW, Gebretsadik T, Mayo G, et al. Relationships between CYP2B6 polymorphisms and pharmacokinetics following a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199: 872-880
22. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791:137-147
23. Rezk NL, Crutchley RD, Yeh RF, Kashuba AD. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit 2006;28:517-525
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265 (Pubitemid 40202029)
25. Liu K, Muse SV PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005;21:2128-2129 (Pubitemid 40668066)
26. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of HardyWeinberg equilibrium. Am J Hum Genet 2005; 76:887-893
27. Ensembl Genome Browser. Ensembl Web site. Available at: http://www.ensembl.org/index.html. Accessed 27 January 2009.
28. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expression. J Pharmacol Exp Ther 2003; 307:906-922
29. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-933 (Pubitemid 32165347)
30. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296:769-781 (Pubitemid 44223101)
31. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologie failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007;46:547-554 (Pubitemid 350191047)
32. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV- 1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-36 (Pubitemid 34119193)
33. Hofmann MH, Blievemicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-292
34. Rotger M, Saumoy M, Zhang K, et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17:885-890 (Pubitemid 47462302)
35. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-309
36. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309 (Pubitemid 33096456)
37. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75 (Pubitemid 32055781)
38. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologie failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-870
39. Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227 [abstract PL5 6], In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection (Glasgow, Scotland), 12-16 November 2006.